Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pileri

Showing results (691-700 of 992) with videos related to

Pageof 100
Sort By:
Haematologica|October 6, 1999
An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapyM Boccadoro, C Tarella, A Palumbo, et al.
Haematologica|February 13, 2008
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemiaBrunangelo Falini, Cristina Mecucci, Giuseppe Saglio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2007
Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphomaPier Luigi Zinzani, Gerardo Musuraca, Monica Tani, et al.
Cellular Immunology|October 13, 2022
Dampening of cytotoxic innate lymphoid cells: A new tumour immune escape mechanism in B cell non-Hodgkin's lymphomaStefania Roma, Chiara Camisaschi, Patrizia Mancuso, et al.
British Journal of Haematology|March 1, 1996
Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID miceA Terenzi, A Bolognesi, L Pasqualucci, et al.
Dermatologic Therapy|August 14, 2020
Cutaneous adverse-events in patients treated with IbrutinibAlessandro Pileri, Alba Guglielmo, Claudio Agostinelli, et al.
British Journal of Haematology|May 25, 2002
Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small- and large-scale Miltenyi cell sorting systemClaudia Voena, Giovanni Locatelli, Claudia Castellino, et al.
Haematologica|March 26, 2003
Primary bone lymphoma: experience with 52 patientsPier Luigi Zinzani, Giovanna Carrillo, Stefano Ascani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2013
Ligand-dependent activation of EGFR in follicular dendritic cells sarcoma is sustained by local production of cognate ligandsWilliam Vermi, Emanuele Giurisato, Silvia Lonardi, et al.
Blood|July 27, 2000
Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusionM Magni, M Di Nicola, L Devizzi, et al.
Pageof 100

Showing results (691-700 of 992) with videos related to

Sort By:
Pageof 100
Haematologica|October 6, 1999
An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapyM Boccadoro, C Tarella, A Palumbo, et al.
Haematologica|February 13, 2008
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemiaBrunangelo Falini, Cristina Mecucci, Giuseppe Saglio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2007
Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphomaPier Luigi Zinzani, Gerardo Musuraca, Monica Tani, et al.
Cellular Immunology|October 13, 2022
Dampening of cytotoxic innate lymphoid cells: A new tumour immune escape mechanism in B cell non-Hodgkin's lymphomaStefania Roma, Chiara Camisaschi, Patrizia Mancuso, et al.
British Journal of Haematology|March 1, 1996
Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID miceA Terenzi, A Bolognesi, L Pasqualucci, et al.
Dermatologic Therapy|August 14, 2020
Cutaneous adverse-events in patients treated with IbrutinibAlessandro Pileri, Alba Guglielmo, Claudio Agostinelli, et al.
British Journal of Haematology|May 25, 2002
Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small- and large-scale Miltenyi cell sorting systemClaudia Voena, Giovanni Locatelli, Claudia Castellino, et al.
Haematologica|March 26, 2003
Primary bone lymphoma: experience with 52 patientsPier Luigi Zinzani, Giovanna Carrillo, Stefano Ascani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2013
Ligand-dependent activation of EGFR in follicular dendritic cells sarcoma is sustained by local production of cognate ligandsWilliam Vermi, Emanuele Giurisato, Silvia Lonardi, et al.
Blood|July 27, 2000
Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusionM Magni, M Di Nicola, L Devizzi, et al.
Pageof 100